Market Research Logo

Global Microbiome Partnering 2012-2018

Global Microbiome Partnering 2012-2018
The Global Microbiome Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Microbiome partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Microbiome partnering contract documents
Top Microbiome deals by value

The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Microbiome agreements announced in the healthcare sectors, covering:

Microbiome
Aminoglycosides
Cephalosporin
Clindamycin
Macrolides
Penicillin
Quinolones
Sulfonamides
Tetracycline

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active Microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Microbiome dealmaking with a brief summary followed by a comprehensive listing of Microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Microbiome partnering company A-Z, deal type definitions and Microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Microbiome partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Microbiome technologies and products.

Report scope

Global Microbiome Partnering Terms and Agreements 2010 to 2018 is intended to provide the reader with an in-depth understanding and access to Microbiome trends and structure of deals entered into by leading companies worldwide.

Global Microbiome Partnering Terms and Agreements 2010 to 2018 includes:

Trends in Microbiome dealmaking in the biopharma industry since 2010
Analysis of Microbiome deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Microbiome deals
Access to over 200 Microbiome deal records and contract documents where available
The leading antibody deals by value since 2010
Most active Microbiome dealmakers since 2010
The leading Microbiome partnering resources

In Global Microbiome Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


  • Executive Summary
  • Introduction
  • Trends in Microbiome dealmaking
    • Introduction
    • Microbiome partnering over the years
    • Most active Microbiome dealmakers
    • Microbiome partnering by deal type
    • Microbiome partnering by therapy area
    • Deal terms for Microbiome partnering
      • Microbiome partnering headline values
        • Table Microbiome deals with a headline value
      • Microbiome deal upfront payments
        • Table Microbiome deals with an upfront value
      • Microbiome deal milestone payments
        • Table Microbiome deals with a milestone value
      • Microbiome royalty rates
  • Leading Microbiome deals
    • Introduction
    • Top Microbiome deals by value
      • Table Top Microbiome deals by value since 2010
  • Most active Microbiome dealmakers
    • Introduction
    • Most active Microbiome dealmakers
    • Most active Microbiome partnering company profiles
      • Enterome Bioscience
      • Seres Therapeutics
      • Second Genome
      • Vedanta Biosciences
      • Ferring Pharmaceuticals
      • Mayo Clinic
      • Diversigen
      • Johnson & Johnson Innovation
      • Bristol-Myers Squibb
      • Janssen Research & Development
      • Johnson & Johnson Consumer Companies
      • National Institutes of Health
      • Zymo Research
      • American Type Culture Collection (ATCC)
      • Bertin Pharma
      • CoreBiome
      • Crohn's and Colitis Foundation of America
      • DayTwo
      • Evelo Biosciences
      • Finch Therapeutics
      • Harvard University
      • Human Longevity
      • Janssen Biotech
      • Janssen Human Microbiome Institute
      • J Craig Venter Institute
  • Microbiome contracts dealmaking directory
    • Introduction
    • Microbiome contracts dealmaking directory
  • Microbiome dealmaking by technology type
    • Microbiome
  • Partnering resource center
    • Online partnering
    • Partnering events
  • Appendices
    • Microbiome deals by company A-Z
      • 4D Pharma
      • Abbvie
      • AIDS Clinical Trials Group
      • Alimentary Health
      • Allergan
      • Amag Pharmaceuticals
      • American Type Culture Collection (ATCC)
      • Ariana Pharma
      • Assembly Biosciences
      • Azitra
      • Baylor Miraca Genetics Laboratories
      • Bertin Pharma
      • Bill and Melinda Gates Foundation
      • Biocodex Microbiota Foundation
      • Biocore
      • Biofortis
      • Biomecite Diagnostics
      • Biomillenia
      • Biosortia Pharmaceuticals
      • Boston University School of Medicine
      • Bristol-Myers Squibb
      • Cedars-Sinai Medical Center
      • Centers for Disease Control and Prevention
      • Centre Leon Berard
      • Centre National de la Recherche Scientifique
      • Clalit Health Services
      • Commense
      • Companion PBx
      • CoreBiome
      • CosmosID
      • Crohn's and Colitis Foundation of America
      • CryoXtract
      • DayTwo
      • Dermala
      • Diversigen
      • DuPont Pioneer
      • Emulate
      • EnBiotix
      • Enterome Bioscience
      • EpiBiome
      • Evelo Biosciences
      • Evogene
      • Evolve BioSystems
      • Evotec
      • ExeGi Pharma
      • Ferring Pharmaceuticals
      • Finch Therapeutics
      • Forsyth Institute
      • French National Institute for Agricultural Research
      • Galmed Pharmaceuticals
      • Genentech
      • General Automation Lab Technologies
      • Genetic Analysis
      • Genewiz
      • GenomeQuest
      • Georges Francois Leclerc Center
      • German Cryo
      • Hackensack Meridian Health
      • Hamilton Company
      • Harvard School of Public Health
      • Harvard University
      • Holobiome
      • Hospital of University of Strasbourg
      • Human Longevity
      • Hy Laboratories
      • IBM
      • Inserm
      • Institute For Life Science Entrepreneurship (ILSE)
      • Institut De Recherche Pour Le Developpement (IRD)
      • Institut Gustave Roussy
      • Institut National Recherche Agronomique
      • Intract Pharma
      • Intralytix
      • Ipsen
      • ISOThrive
      • Jackson Laboratory
      • Janssen Biotech
      • Janssen Human Microbiome Institute
      • Janssen Research & Development
      • Johnson & Johnson Consumer Companies
      • Johnson & Johnson Innovation
      • Johns Hopkins University
      • JSR
      • J Craig Venter Institute
      • Kaleido Biosciences
      • Karolinska Institute
      • Keio Gijuku University
      • Kenneth Rainin Foundation (KRF)
      • King's College Hospital
      • Kings College London
      • Lawrence Livermore National Laboratory
      • Leiden University
      • Leidos
      • Locus Biosciences
      • MaaT Pharma
      • Massachusetts General Hospital
      • Mayo Clinic
      • MD Anderson Cancer Center
      • Medical College of Wisconsin
      • Medical University of Graz
      • Memorial Sloan Kettering Cancer Center
      • MetaboGen
      • Metabolon
      • Metagenics
      • Metanome
      • Microbiotica
      • MilliporeSigma
      • Monsanto
      • MyBiotics Pharma
      • National Institutes of Health
      • National Institute of Allergy and Infectious Diseases
      • National Institute of Arthritis and Musculoskeletal Diseases
      • National Institute of Diabetes and Digestive and Kidney Diseases
      • National Psoriasis Foundation
      • Nestle Health Science
      • Norgen Biotek
      • North Zealand University Hospital
      • NuBiyota
      • NYU Langone Medical Center
      • Oncodesign
      • One Codex
      • OpenBiome
      • OpGen
      • OptiBiotix
      • OSEO
      • Owlstone Medical
      • Pathogenica
      • Pfizer
      • Pharmatest Services
      • Pierre Fabre
      • PureTech Health
      • Qiagen
      • Quark Venture
      • Rebiotix
      • Ritter Pharmaceuticals
      • Roswell Park Cancer Institute
      • Ruggles Family Foundation
      • SACCO
      • Salix Pharmaceuticals
      • Sanofi
      • SATT Lutech
      • Second Genome
      • Seres Therapeutics
      • Servier
      • Sirenas
      • Stanford Cancer Institute
      • Stanford University School of Medicine
      • Symbiotix Biotherapies
      • Synergie Lyon Cancer
      • Synlogic
      • Synthetic Biologics
      • Taconic Biosciences
      • Takeda Pharmaceutical
      • The BioCollective
      • The Parker Institute For Cancer Immunotherapy
      • Toulouse University Hospital
      • Transgene
      • UBiome
      • UCB
      • University College Cork
      • University College Hospital, Ibadan
      • University of Adelaide
      • University of Alberta
      • University of British Columbia
      • University of California, San Diego
      • University of California, San Diego (UCSD) School of Medicine
      • University of Cape Town
      • University of Chicago
      • University of Cincinnati
      • University of Heidelberg
      • University of Maryland
      • University of Maryland Institute for Genome Sciences (IGS)
      • University of Maryland Ventures
      • University of Nebraska
      • University of Pennsylvania
      • University of Rhode Island
      • University of South Alabama (USA) Mitchell Cancer Institute
      • University of Texas
      • University Pierre Marie Curie
      • Vedanta Biosciences
      • Vertex Pharmaceuticals
      • Washington University in St Louis
      • Weizmann Institute
      • Wellcome Trust
      • Western Connecticut Health Network
      • Xycrobe Therapeutics
      • Yeda Research and Development Company
      • Zymo Research
    • Microbiome deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Marketed
    • Microbiome deals by deal type
      • Asset purchase
      • Co-development
      • Collaborative R&D
      • Development
      • Distribution
      • Grant
      • Licensing
      • Manufacturing
      • Marketing
      • Option
      • Research
      • Sub-license
      • Supply
      • Termination
    • Microbiome deals by therapy area
      • Cardiovascular
      • Multiple sclerosis
      • Dental
      • Dermatology
      • Acne
      • Dermatitis
      • Eczema
      • Psoriasis
      • Gastrointestinal
      • Inflammatory bowel disease
      • Crohn's disease
      • Ulcerative colitis
      • Irritable bowel syndrome
      • Constipation
      • Diarrhea
      • Genetic disorders
      • Sickle cell disease
      • Gynaecology
      • Transplantation
      • Immunology
      • AIDS
      • Allergy
      • Graft versus host disease
      • Inflammation
      • Infectives
      • Bacterial
      • Clostridium difficile
      • Viral
      • HIV
      • Metabolic
      • Diabetes
      • Type 2
      • Liver disease
      • Nonalcoholic steatohepatitis (NASH)
      • Nutrition and vitamins
      • Pregnancy
      • Preterm labour
      • Oncology
      • Cervical cancer
      • Colorectal cancer
      • Bone metastases
      • Orphan disease
      • Pediatrics
      • Sleep disorders
      • Obesity
      • Respiratory
      • Asthma
      • Pneumonia
      • Wheeze
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report